Search results
Results from the WOW.Com Content Network
Raytheon will pay a $146.8 million criminal penalty to resolve that criminal fraud case and another $428 million to resolve related civil claims brought under the False Claims Act.
RTX Corporation, the defense contractor formerly known as Raytheon, agreed Wednesday to pay more than $950 million to resolve allegations that it defrauded the government and paid bribes to secure ...
At the center of the allegations in the Massachusetts case are missile systems Raytheon sold to the Department of Defense from 2011 to 2013 and the operation of a radar surveillance system in 2017 ...
United States Court of Federal Claims: 2013 Conant v. McCaffrey: right to recommend medical marijuana: United States district court: Daniels v. City of New York: racial profiling and unlawful stop and frisk: De Beers Diamonds Antitrust Litigation: U.S. District Court for the District of New Jersey: Doe v. Chiquita Brands International
RTX Corporation, formerly Raytheon Technologies Corporation, [3] [4] is an American multinational aerospace and defense conglomerate headquartered in Arlington, Virginia.It is one of the largest aerospace and defense manufacturers in the world by revenue and market capitalization, as well as one of the largest providers of intelligence services.
In January 2021, a number of companies halted their political contributions in the United States, primarily in response to some Republican legislators' objections to certification of the 2021 United States Electoral College vote count and the ensuing mob that attacked the U.S. Capitol.
Raytheon Missiles & Defense (RMD) was one of four business segments of RTX Corporation. Headquartered in Tucson, Arizona, its president was Wes Kremer. [ 1 ] The business produced a broad portfolio of advanced technologies, including air and missile defense systems, precision weapons, radars, and command and control systems. [ 2 ]
The following are settlements reached with US authorities against pharmaceutical companies to resolve allegations of "off-label" promotion of drugs. Under the Federal Food, Drug, and Cosmetic Act, it is illegal for pharmaceutical companies to promote their products for uses not approved by the Food and Drug Administration (FDA), and corporations that market drugs for off-label indications may ...